Renovascular HTN. Intravascular hypokalemia. Dual blockade of RAAS. Not recommended in concomitant use w/ RAAS. Acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure in patients whose vascular tone & renal function depend on RAAS. Primary aldosteronism. Aortic & mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Diabetic patients treated w/ insulin or antidiabetics. Hyperkalemia. Fructose intolerance. Black hypertensive population. Renal impairment. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn <18 yr.